AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01672593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy exploration and glue application
Description: A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device. Upon injection, two components, fibrinogen and thrombin, were mixed together in the mixing reservoir and yield a gelatin-like glue. This procedure was repeated in patients up to 3 times within 14-day FG treatment period.
Study NCT01672593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Bacterial Agents
Description: Antibacterial therapy was given to patients with signs of systemic sepsis or local inflammation with pain.
Study NCT01672593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Bacterial Agents
Description: Antibacterial therapy was given to patients with signs of systemic sepsis or local inflammation with pain.
Study NCT01672593 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition support
Description: Nutritional replacement and bowel rest via enteral or parenteral nutrition.
Study NCT01672593 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition support
Description: Nutritional replacement and bowel rest via enteral or parenteral nutrition.
Study NCT01672593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRFG preparation
Description: As described in our previous work, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the PRFG group and then frozen at -20°C for storage.
Study NCT01694888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lecture
Description: Teaching documentation skill using lecture method
Study NCT00561899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP, amodiaquine, piperaquine, dihdroartemisinin
Description: once every month during september, October and November
Study NCT00561899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intermittent preventive treatment
Description: SP(500mg sulfadoxine/25mg pyrimethamine)1.25mg SP per kg stat Amodiaquine (200mg base) 25mg/kg over 3 days Piperaquine (320 mg per tablet) 16.8 g/kg daily for 3 days Du-Cotecxin ( 40mg dihydroartemisinin(DHA)/320mg piperaquine(PQP))PQP/DHA 1.6/12.8mg/kg once daily for 3 days
Study NCT00561899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Du-Cotecxin
Description: Du-Cotecxin (40mg dihydroartemisinin (DHA/320mg Piperaquine (PQP) PQP/DHA 1.6/12.8mg/kg once daily for 3 days
Study NCT04236232 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thyroid function
Description: Thyroid function,Lipid Profile, systolic Blood pressure ,diastolic blood pressure .Body Mass Index ,CRP,Echocardiography،ECG, Ultrasonography of Carotid artery
Study NCT02025855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Study NCT02025855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04576845 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: The children's eating behavior will be evaluated with Turkish validated Children's Eating Behavior Questionnaire - (CEBQ) by interviewing mothers face to face. The CEBQ is a Likert type, parent-report rating scale measuring the variation in eating behavior in children. The CEBQ consists of 35 items comprising eight subscales, each containing 3 to 6 items. Parents will be asked to rate their child's eating behavior on a five-point scale (never, rarely, sometimes, often, always; 1-5, respectively).
Study NCT03451409 — intervention group
Intervention type: OTHER
Intervention: Tasked based functional MRI (fMRI)
Description: 2-3 brief computer tasks while brain activity is being measured. The tasks performed will involve making button press responses to letters, numbers or shapes on the computer screen.
Study NCT03451409 — intervention group
Intervention type: OTHER
Intervention: Eye Tracking Device
Description: Camera aimed at eyes to record eye movements during tasks
Study NCT03527498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baby treadmill
Description: The newborns who received treadmill intervention were stimulated by running 3 times a week for a total of 10 minutes each time (complete in 5 cycles, 2 minutes per cycle, 2 minutes after the completion of one cycle and rest for 2 minutes to start the next cycle). Until the completion and completion of the five cycles). During the remaining four days of each week, other physical rehabilitation training is carried out by the rehabilitator in accordance with the established rehabilitation plan. The stimulation of running lasted from 3 months of corrected gestational age to being able to walk alone for 3 steps or to correct for 18 months.
Study NCT03527498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation training
Description: Suitable for general physical rehabilitation training of all infants with cerebral palsy.
Study NCT03527498 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical rehabilitation training
Description: Suitable for general physical rehabilitation training of all infants with cerebral palsy.
Study NCT01423708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Administration of Everolimus within 24 hours from the time of randomization (7 days from the time of transplantation) in association with Tacrolimus and steroids. The first dose level of the trough will be performed at day 7 after initiation of therapy. After the reaching an Everolimus trough level of >5ng/ml (final target 6-12 ng/ml), there will be a gradual weaning of tacrolimus (bringing Tacrolimus blood levels \<5 ng/ml) with discontinuation of Tacrolimus within 30 days after transplantation when possible.
Study NCT00832000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mexiletine
Description: 200 mg three times a day; in pill form
Study NCT00832000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo three times a day; in pill form
Study NCT02416245 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beverage powder fortified with micronutrients and Bacopa monnieri extract
Description: Test beverage powder is fortified with micronutrients and Bacopa monnieri extract. Each sachet contains 32g of treatmemt product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
Study NCT02416245 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non fortified isocaloric control (without added micronutrients and Bacopa monnieri extract)
Description: Control beverage powder is the non-fortified isocaloric powder i.e. without micronutrients and Bacopa Monnieri extract. Each sachet contains 32g of placebo product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
Study NCT03562429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGF
Description: TGF is a powder formulation of Hu-Qian Wan (HQW). HQW is composited of 10 herbs, Chinemys reevesii (Gray), Phellodendron chinense Schneid., Achyranthes bidentata Blume, Anemarrhena asphodeloides Bunge, Rehmannia glutinosa Libosch., Paeonia lactiflora Pall., Cynomorium songaricum Rupr., Angelica sinensis (Oliv.) Diels, Citrus reticulata Blanco and Zingiber officinale Rosc..
Study NCT03562429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TGFP
Description: TGFP is 1/20 concentration of Hu-Qian Wan (HQW). HQW is composited of 10 herbs, Chinemys reevesii (Gray), Phellodendron chinense Schneid., Achyranthes bidentata Blume, Anemarrhena asphodeloides Bunge, Rehmannia glutinosa Libosch., Paeonia lactiflora Pall., Cynomorium songaricum Rupr., Angelica sinensis (Oliv.) Diels, Citrus reticulata Blanco and Zingiber officinale Rosc..
Study NCT01651533 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Practice Group
Description: Patients are administered rehabilitative therapy targeting their affected arms on 3 days/week during a ten week period. Directly after the therapy session, they participate in targeted mental practice session in which they cognitively rehearse the movement that they just physically practiced.
Study NCT01651533 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Group
Description: Individuals assigned to this group are administrated rehabilitative therapy targeting their affected arms in half four increments, occurring 3 days/week for 10 weeks. They also are administered an intervention in which they listen to a relaxation tape and/or tapes in which they receive instructions on exercises and information on stroke care.
Study NCT02400814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-L1 Monoclonal Antibody MPDL3280A
Description: Given IV
Study NCT02400814 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SAR
Study NCT02019641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training (AET)
Description: walking on a treadmill at vigorous intensity for up to 45 minutes
Study NCT02019641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Weekly education
Study NCT02019641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Weekly education
Study NCT03856047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174-0833
Description: Participants will get one dose of NNC0174-0833 once weekly. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
Study NCT03856047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0174-0833)
Description: Participants will get one dose of Placebo (NNC0174-0833) once weekly. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
Study NCT03856047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide 3.0 mg
Description: Participants will get one dose of liraglutide 3.0 mg once daily. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using pre-filled PDS290 pen-injector. Participants will gradually increase their dose every week until they reach the target dose of 3.0 mg daily. The participants will continue on 3.0 mg of liraglutide, once daily up to 26 weeks.
Study NCT03856047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Liraglutide 3.0 mg)
Description: Participants will get one dose of Placebo (liraglutide 3.0 mg) once daily. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using pre-filled PDS290 pen-injector. Participants will gradually increase their dose every week until they reach the target dose of 3.0 mg. The participants will continue on Placebo (liraglutide 3.0 mg), once daily up to 26 weeks.
Study NCT02734186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel
Description: Anthelminthic
Study NCT04016805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: * recombinant chimeric anti-CD20 monoclonal antibody~* administered as an IV infusion
Study NCT04016805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: * Phosphoinositide-3-kinase (PI3K) delta inhibitor~* Tablet form, to taken orally on a daily basis
Study NCT04016805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: * Bruton Tyrosine Kinase (BTK) inhibitor~* Tablet form, to taken orally on a daily basis
Study NCT04016805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: * BCL-2 inhibitor~* Tablet form, to be taken orally
Study NCT04016805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib Oral Capsule
Description: Kinase inhibitor, capsule form, to be taken orally
Study NCT01101061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection
Study NCT01101061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study NCT02591862 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Coversin
Description: Patients enrolled in this protocol will initially be treated with an ablating dose of Coversin and daily repeat maintenance doses calculated according to body weight, the ablating dose to be 0.57mg/kg. Thereafter the daily repeat dose will be titrated according to clinical response and complement inhibition determined by CH50 ELISA. The initial repeat dose will be 25% of the ablating dose and this will be adjusted up or down if necessary once steady state is reached (5 days).
Study NCT02931578 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose100
Study NCT02931578 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose50
Study NCT02931578 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose42
Study NCT02931578 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Tolerance Test
Description: For each OGTT, subjects will consume 50g of sweetener dissolved in water at a comfortable pace within 10 minutes. Blood samples for plasma glucose and insulin will be taken at -20, 0, 15, 30, 45, 60, 90 and 120 min after consuming the glucose drink. Plasma fructose will be tested at baseline, 30, 60, 90 and 120 minutes.
Study NCT04419363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Burosumab Injection
Description: Children affected with X-linked hypophosphatemia were switched from conventional therapy to burosumab
Study NCT02868372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone iodine
Description: After closure of the anterior wall of the rectus sheath, the subcutaneous tissues of the cesarean section wound will be swabbed with 10% undiluted Povidone iodine without mobbing.
Study NCT02023749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nut group
Study NCT05174598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol/AKVANO, 50 μg/g cutaneous solution
Description: Topical spray formulation containing Calcipotriol 50 μg/g. Twice daily treatment by spraying on a psoriasis affected area for 8 weeks.
Study NCT05174598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol Ointment 50 micrograms/g
Description: Topical Ointment formulation containing Calcipotriol 50 micrograms/g. Twice daily treatment by applying on a psoriasis affected area for 8 weeks.
Study NCT05174598 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical spray formulation containing Vehicle of test formulation. Twice daily treatment by spraying on a psoriasis affected area for 8 weeks.
Study NCT00770588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Dose form: 250 mg/tablet; Route: oral; Frequency: 1 tablet per day; Duration: until to objective PD
Study NCT00770588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To match Gefitinib
Study NCT00543153 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview lasting approximately 30-45 minutes.
Study NCT03716765 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: locally injected vitamin D
Description: locally injected vitamin d as non surgical method for periodontal regeneration of vertical bony defects
Study NCT03716765 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: locally injected vitamin D
Description: locally injected vitamin d as non surgical method for periodontal regeneration of vertical bony defects
Study NCT01137747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Study NCT01426113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost ophthalmic solution formulation A
Description: 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the evening for 6 weeks, followed by 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the morning for 6 weeks.
Study NCT01426113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol ophthalmic solution
Description: 1 drop timolol ophthalmic solution in the affected eye(s) in the morning and evening for 12 weeks.
Study NCT01426113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost vehicle
Description: 1 drop of bimatoprost vehicle in the affected eye(s) in the morning for 6 weeks, followed by 1 drop of bimatoprost vehicle in the affected eye(s) in the evening for 6 weeks.
Study NCT00728299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PomWonderful Juice
Description: 8 oz per day each day for 78 weeks
Study NCT00728299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo juice
Description: 8 oz per day for 78 weeks
Study NCT00002668 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Study NCT00002668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention and Behavioral Skills Training
Study NCT04539067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HHMG
Description: Induction of ovulation from the 2nd day of cycle to 5th day then follow the diameter of follicle Use transvaginal ultrasound When diameter of follicle 18 to 22 patients receiving HMG
Study NCT02219399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 600 mg DHA
Description: Pregnant women were given 600 mg DHA in the last trimester of pregnancy
Study NCT02219399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 300 mg DHA
Description: Pregnant women were given 300 mg DHA in the last trimester of pregnancy and through the first 3 months of breastfeeding
Study NCT02219399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pregnant women in the control group received placebo of either olive oil or high oleic acid sunflower oil during the study period
Study NCT02276534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SENSE Theatre
Description: A peer-mediated, theatre-based intervention.
Study NCT02276534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed Intervention
Study NCT03336099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spa Treatment
Description: * Bath with immersion shower~* Overall shower, penetrating shower~* Multiple local application cataplasm~* Single local application cataplasm~* Inhalation or collective steam bath~* Individual physiotherapy technique
Study NCT02429986 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Adaptive Servo-Ventilation
Description: Adaptive Servo-Ventilation proceeds by continually measuring either minute ventilation or airflow and calculates a target ventilation to be applied as needed.
Study NCT02353416 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Glycemic Index Mediterranean Diet
Description: Prescription of a Low Glycemic Index (less than 50) Mediterranean Diet with no more than 10% of total daily calories coming from saturated fats, high in monounsaturated fatty acids (MUFA) from olive oil and omega-3 polyunsaturated fatty acids (ω3PUFA), from both plant and marine sources
Study NCT02353416 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: INRAM Guidelines' diet
Description: Prescription of INRAM guidelines' diet
Study NCT00732992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib, Pemetrexed
Description: Sunitinib daily by oral capsule in a continuous daily dosing regimen with pemetrexed every 3 weeks until progression or unacceptable toxicity.
Study NCT00732992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib, Pemetrexed
Description: Sunitinib daily by oral capsule administered for 2 weeks out of every 3 weeks with pemetrexed every 3 weeks until progression or unacceptable toxicity.
Study NCT02944396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: intravenous; administered on Day 1 via infusion in a 21-day cycle
Study NCT02944396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: intravenous; administered on Day 1 via infusion in a 21-day cycle
Study NCT02944396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: intravenous; administered on Day 1 via infusion in a 21-day cycle
Study NCT02944396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: oral capsule; varying doses administered on Days -2 to 5 in a 21-day cycle
Study NCT02944396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: intravenous; administered on Day 1 via infusion in a 21-day cycle
Study NCT00728000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 IV on day 1 and day 15 over 30mins.
Study NCT00728000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 100mg/m2 IV on days 1 and 15 given over 120 mins.